Cargando...

Phase 1 Study of Alisertib (MLN8237) and Weekly Irinotecan in Adults with Advanced Solid Tumors

PURPOSE: Aurora kinases are overexpressed or amplified in numerous malignancies. This study was designed to determine the safety and tolerability of the Aurora A kinase inhibitor alisertib (MLN8237) when combined with weekly irinotecan. METHODS: In this single center phase 1 study, adult patients wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Autores principales: Semrad, Thomas J., Kim, Edward J., Gong, I-Yeh, Li, Tianhong, Christensen, Scott, Arora, Mili, Riess, Jonathan W., Gandara, David R., Kelly, Karen
Formato: Artigo
Lenguaje:Inglês
Publicado: 2021
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8259450/
https://ncbi.nlm.nih.gov/pubmed/33993383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04293-3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!